<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521413</url>
  </required_header>
  <id_info>
    <org_study_id>TWT-101</org_study_id>
    <nct_id>NCT04521413</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies</brief_title>
  <official_title>A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Treadwell Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TIO Discovery Engine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Treadwell Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of an investigational drug called CFI-402411&#xD;
      alone and in combination with pembrolizumab and to study its effects in patients with&#xD;
      advanced solid tumors who have progressed following previous therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a first-in-human study evaluating the safety and tolerability of&#xD;
      CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a&#xD;
      single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the&#xD;
      function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in&#xD;
      patients. This immune response could be further enhanced when combined with pembrolizumab.&#xD;
      The data obtained from this study will determine the dose and schedule and subject selection&#xD;
      for further clinical studies.&#xD;
&#xD;
      Pre-clinical findings support further development of CFI-402411 as a novel anti-cancer agent,&#xD;
      and the combination of CFI-402411 with pembrolizumab as a potential strategy to improve&#xD;
      outcomes of subjects with advanced malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation and expansion for monotherapy and combination arms with pembrolizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D).</measure>
    <time_frame>48 months</time_frame>
    <description>The number of subjects who experience an adverse event that was possibly related to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D.</measure>
    <time_frame>48 months</time_frame>
    <description>The number of subjects who experience an adverse event that was possibly related to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To examine best overall response rate in subjects treated at multiple dose levels of CFI-402411.</measure>
    <time_frame>48 months</time_frame>
    <description>Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To examine progression free survival in subjects treated at multiple dose levels of CFI-402411.</measure>
    <time_frame>48 months</time_frame>
    <description>Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify the maximum tolerated dose of single agent CFI-402411 alone and in combination with pembrolizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>Safety tables and pharmacokinetic tables will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further assess the incidence of adverse events of CFI-402411.</measure>
    <time_frame>48 months</time_frame>
    <description>The number of subjects who experience an adverse event that was possibly related to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess best overall response of CFI-402411 monotherapy and in combination with pembrolizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess overall response rates of CFI-402411 monotherapy and in combination with pembrolizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>For all subjects the overall response rates of complete response and partial response will be calculated and summarized by dose cohort and overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess overall survival of CFI-402411 monotherapy and in combination with pembrolizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>The time from first dose until the date of death from any cause will be calculated and summarized for all patients by dose cohort and overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess progression free survival of CFI-402411 monotherapy and in combination with pembrolizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess duration of response of CFI-402411 monotherapy and in combination with pembrolizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>The time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first, will be calculated and summarized for all patients by dose cohort and overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through AUC.</measure>
    <time_frame>48 months</time_frame>
    <description>Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Cmax.</measure>
    <time_frame>48 months</time_frame>
    <description>Cmax will be assessed through the maximum measured plasma concentration occurring at Tmax tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Tmax.</measure>
    <time_frame>48 months</time_frame>
    <description>Tmax will be assessed by the time to achieve maximum plasma concentration and will be tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab though Cmin.</measure>
    <time_frame>48 months</time_frame>
    <description>Cmin will be calculated through the measured pre-dose plasma concentration and tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through T1/2.</measure>
    <time_frame>48 months</time_frame>
    <description>Elimination half life will be calculated and tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of CFI-402411 treatment on immune- or disease related biomarkers.</measure>
    <time_frame>48 months</time_frame>
    <description>The effects of CFI-402411 on pharmacodynamic biomarkers (cytokine levels) will be assessed by percent changes from baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>A1: Monotherapy Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2: Monotherapy Biomarker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3: Monotherapy Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion arm with CFI-402411 at its recommended phase 2 dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1: Combination Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2: Combination Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFI-402411</intervention_name>
    <description>CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.</description>
    <arm_group_label>A1: Monotherapy Escalation</arm_group_label>
    <arm_group_label>A2: Monotherapy Biomarker</arm_group_label>
    <arm_group_label>A3: Monotherapy Expansion</arm_group_label>
    <arm_group_label>B1: Combination Escalation</arm_group_label>
    <arm_group_label>B2: Combination Expansion</arm_group_label>
    <other_name>2411</other_name>
    <other_name>402411</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.</description>
    <arm_group_label>B1: Combination Escalation</arm_group_label>
    <arm_group_label>B2: Combination Expansion</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>pembro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria: Study-Wide Eligibility (Across All Study Parts):&#xD;
&#xD;
          1. Age &gt; 18 years old&#xD;
&#xD;
          2. Have progressed after â‰¥ 1, but no more than 3 regimens of systemic therapies for&#xD;
             recurrent / metastatic disease.&#xD;
&#xD;
          3. Subjects must have measurable disease.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
        Part A1: Monotherapy Dose Escalation Inclusion Criteria&#xD;
&#xD;
        1. Histological or cytological confirmation of advanced solid malignancy that is refractory&#xD;
        to or not a candidate for current standard treatment(s) and for whom no standard therapy is&#xD;
        available.&#xD;
&#xD;
        Part A2: Biomarker-Focused Monotherapy Backfills Inclusion Criteria&#xD;
&#xD;
          1. Histological or cytological confirmation of one of the advanced cancers listed below;&#xD;
&#xD;
               -  NSCLC&#xD;
&#xD;
               -  SCLC&#xD;
&#xD;
               -  cutaneous melanoma&#xD;
&#xD;
               -  Merkel cell carcinoma&#xD;
&#xD;
               -  squamous cell carcinoma of head and neck, anal canal, or skin&#xD;
&#xD;
               -  urothelial cancer&#xD;
&#xD;
               -  clear cell or non-clear cell renal cell carcinoma&#xD;
&#xD;
               -  triple negative breast cancer&#xD;
&#xD;
               -  endometrial cancer (regardless of MSI status)&#xD;
&#xD;
               -  cervical cancer&#xD;
&#xD;
               -  gastroesophageal cancer&#xD;
&#xD;
               -  hepatocellular cancer&#xD;
&#xD;
               -  any histology if known to be microsatellite-instability high (MSI-H)&#xD;
&#xD;
          2. Tumors must be refractory to or not a candidate for current standard treatment(s) and&#xD;
             for whom no standard therapy exists.&#xD;
&#xD;
        Part A3: Monotherapy Expansion Inclusion Criteria&#xD;
&#xD;
          1. Histological or cytological confirmation of one of the advanced cancers listed below;&#xD;
&#xD;
               -  NSCLC cancer any histology&#xD;
&#xD;
               -  SCLC&#xD;
&#xD;
               -  cutaneous melanoma&#xD;
&#xD;
               -  Merkel cell carcinoma&#xD;
&#xD;
               -  squamous cell carcinoma of head and neck, anal canal, or skin&#xD;
&#xD;
               -  urothelial cancer&#xD;
&#xD;
               -  clear cell or non-clear cell renal cell carcinoma&#xD;
&#xD;
               -  triple negative breast cancer&#xD;
&#xD;
               -  endometrial cancer (regardless of MSI status)&#xD;
&#xD;
               -  cervical cancer&#xD;
&#xD;
               -  gastroesophageal cancer&#xD;
&#xD;
               -  hepatocellular&#xD;
&#xD;
               -  any histology if known to be microsatellite-instability high (MSI-H)&#xD;
&#xD;
          2. Tumors must be refractory to or subjects intolerant of current standard treatment(s)&#xD;
             and for whom no standard therapies are available.&#xD;
&#xD;
          3. Optional biopsies: Subjects that consent to optional fresh tumor biopsies must have at&#xD;
             least one non-target soft tissue tumor lesion that can be biopsied.&#xD;
&#xD;
        Part B1: CFI-402411 in Combination with Pembrolizumab Dose Escalation Inclusion Criteria&#xD;
&#xD;
          1. Subjects must be deemed eligible by the Investigator to receive pembrolizumab.&#xD;
&#xD;
          2. Histological or cytological confirmation of one of the advanced cancers listed below&#xD;
             (list may vary in each country, USA shown here);&#xD;
&#xD;
               -  NSCLC cancer any histology&#xD;
&#xD;
               -  SCLC&#xD;
&#xD;
               -  cutaneous melanoma&#xD;
&#xD;
               -  Merkel cell carcinoma&#xD;
&#xD;
               -  squamous cell carcinoma of head and neck, anal canal, or skin&#xD;
&#xD;
               -  urothelial cancer&#xD;
&#xD;
               -  clear cell or non-clear cell renal cell carcinoma&#xD;
&#xD;
               -  triple negative breast cancer&#xD;
&#xD;
               -  endometrial cancer (regardless of MSI status)&#xD;
&#xD;
               -  cervical cancer&#xD;
&#xD;
               -  gastroesophageal cancer&#xD;
&#xD;
               -  hepatocellular cancer&#xD;
&#xD;
               -  any histology if known to be microsatellite-instability high (MSI-H)&#xD;
&#xD;
        Tumors must be refractory to or subjects intolerant of current standard treatment(s) or for&#xD;
        whom no standard therapy is available.&#xD;
&#xD;
        Part B2: CFI-402411 in Combination with Pembrolizumab Expansion Inclusion Criteria&#xD;
&#xD;
          1. Subjects must be deemed eligible by the Investigator to receive pembrolizumab&#xD;
&#xD;
          2. Histological or cytological confirmation of one of the advanced cancers listed below&#xD;
             (list may vary in each country, USA shown here);&#xD;
&#xD;
               -  non-small cell lung cancer any histology&#xD;
&#xD;
               -  SCLC&#xD;
&#xD;
               -  cutaneous melanoma&#xD;
&#xD;
               -  Merkel Cell carcinoma&#xD;
&#xD;
               -  squamous cell carcinoma of head and neck, anal canal, or skin&#xD;
&#xD;
               -  urothelial cancer&#xD;
&#xD;
               -  clear cell or non-clear cell renal cell carcinoma&#xD;
&#xD;
               -  triple negative breast cancer&#xD;
&#xD;
               -  endometrial cancer (regardless of MSI status)&#xD;
&#xD;
               -  gastroesophageal cancer&#xD;
&#xD;
               -  hepatocellular cancer&#xD;
&#xD;
               -  any histology if known to be microsatellite-instability high (MSI-H)&#xD;
&#xD;
          3. Tumors must be refractory to or subjects intolerant of current standard non-IO&#xD;
             treatment(s) or for whom no standard therapy is available.&#xD;
&#xD;
        Key Exclusion Criteria: Study-Wide Eligibility (Across All Study Parts)&#xD;
&#xD;
        Subjects will be excluded from the study if any of the following criteria is met;&#xD;
&#xD;
          1. Previous treatment with an HPK1 inhibitor in other clinical trials.&#xD;
&#xD;
          2. Diagnosis of autoimmune-based disease or clinically significant auto-immune disorders.&#xD;
&#xD;
          3. Have symptomatic congestive heart failure, active angina pectoris or recent myocardial&#xD;
             infarction (within 6 mos).&#xD;
&#xD;
          4. Have chronic atrial fibrillation.&#xD;
&#xD;
          5. Known central nervous system metastasis.&#xD;
&#xD;
          6. Stroke or transient ischemic attack, or other ischemic events or thromboembolic events&#xD;
             within 3 months of study enrollment.&#xD;
&#xD;
          7. A history of QTc prolongation or a marked baseline prolongation of QT/QTc interval or&#xD;
             a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family&#xD;
             history of Long QT Syndrome).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Bendell, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarah Cannon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Treadwell Therapeutics Clinical Trials</last_name>
    <phone>+1-416-455-7510</phone>
    <email>clinicaltrials@treadwelltx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Azada</last_name>
      <email>mazada@theangelesclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Jones</last_name>
      <email>djones@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START - Mid-West</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robinson Katie</last_name>
      <email>katie.robinson@startmidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miller Elizabeth</last_name>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munir Chowdhury</last_name>
      <email>MChowdhury@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez</last_name>
      <email>isabel.jimenez@startsa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hackmaster</last_name>
      <email>melissa.hackmaster@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Adile</last_name>
      <email>ashley.adile@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Koh</last_name>
      <email>Jane@clo.cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced tumors</keyword>
  <keyword>pembro</keyword>
  <keyword>keytruda</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>2411</keyword>
  <keyword>CFI-402411</keyword>
  <keyword>first in human</keyword>
  <keyword>first-in-human</keyword>
  <keyword>hematopoietic progenitor kinase-1 inhibitor</keyword>
  <keyword>HPK1</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>solid malignancies</keyword>
  <keyword>TWT-101</keyword>
  <keyword>TWT101</keyword>
  <keyword>UHN</keyword>
  <keyword>University Health Network</keyword>
  <keyword>Treadwell Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is too early to determine whether we will make IPD available - we do not yet have a process written on this. Field will be updated once our policy / process is written.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

